Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia

British Journal of Cancer

Volumn 73, Issue 7, 1996, Pages 866-871

  Colombo, T ^a   Gonzalez Paz, O ^a   D'Incalci, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Doxorubicin reversing agent; Resistance; SDZ PSC 833

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GLYCOPROTEIN P; VALSPODAR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LEUKEMIA CELL; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029921377     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.154     Document Type: Article

References (28)

1. BOESCH D AND LOOR F. (1994). Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents. Anticancer Drugs, 5, 229-238.
2. BOESCH D, MULLER K, POURTIER-MANZANEDO A AND LOOR F. (1991a). Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell. Res., 196, 26-32.
3. BOESCH D, GAVERIAUX C, JACHEZ B, POURTIER MANZANEDO A, BOLLINGER P AND LOOR F. (1991b) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumour cell with SDZ PSC 833. Cancer Res., 51, 4226-4233.
4. BROGGINI M, ITALIA C, COLOMBO T, MARMONTI L AND DONELLI MG. (1984). Activity and distribution of i.v. and oral 4-demethoxydaunorubicin in murine experimental tumours. Cancer Treat. Rep., 68, 739-747.
5. CAPRANICO G, SORANZO C AND ZUNINO F. (1986). Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells. Cancer Res., 46, 5499-5503.
6. COLOMBO T, ZUCCHETTI M AND D'INCALCI M. (1994). Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J. Pharmacol. Exp. Ther., 269, 22-27.
7. CROOP JM, RAYMOND M, HABER D, DEVAULT A, ARCECI RJ, GROS P AND HOUSMAN DE. (1989). The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol. Cell. Biol., 9, 1346-1350.
8. D'INCALCI M. (1995). First International Conference on Reversal of Multi-Drug Resistance, St. Gallen, 1-3 September 1994. Ann. Oncol., 5, 893-894.
9. ENDICOTT JA AND LING V. (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58, 137-171.
10. ERLICHMAN C, MOORE M, THIESSEN JJ, KERR IG, WALKER S, GOODMAN P, BJARNASON G, DEANGELIS C AND BUNTING P. (1993). Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res., 53, 4837-4842.
11. FOJO AT, UEDA K, SLAMON DJ, POPLACK DG, GOTTESMAN MM AND PASTAN I. (1987). Expression of a multidrug-resistance gene in human tumours and tissues. Proc. Natl Acad. Sci. U.S.A., 84, 265-269.
12. FORD JM AND HAIT WN. (1990). Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 42, 155-199.
13. FRICHE E, JENSEN PB AND NISSAN NI. (1992). Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumour. Cancer Chemother. Pharmacol., 30, 235-237.
14. GIACCONE G, LINN SC, CATIMEL G, DUMORTIER A, FOY M, VERMOKEN JB, KOIER I, WELINK J, VAN DER VIJGH WJF, EELTINK C, LABURTE C AND PINEDO HM. (1994). SDZ PSC 833 in combination with doxorubicin: a phase I and pharmacologic study in solid tumours (Abstract) (suppl.1). Anticancer Drugs, 5, 42.
15. GONZALEZ O, COLOMBO T, DE FUSCO M, IMPERATORI L, ZUCCHETTI M AND D'INCALCI M. (1985). Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother. Pharmacol., 36, 335-340.
16. GOTTESMAN MM. (1993). How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res., 53, 747-754.
17. GRANDI M, YOUNG C, BELLINI O, GERI O, MUINDI J AND GIULIANI F. (1987). Pleiotropic multidrug resistant LoVo, P388, and I-407 cell lines have an increased tubovesicular compartment (meeting abstract). Proc. Natl Acad. Sci. U.S.A., 28, 279.
18. GROS P, NERIAH YB, CROOP JM AND HOUSMAN DE. (1986). Isolation and expression of a complementary DNA that confers multidrug resistance. Nature, 323, 728-731.
19. ISAACS RJ, DAVIES SL, WELLS NJ AND HARRIS AL. (1995). Topoisomerases IIa and b as therapy targets in breast cancer. Anticancer Drugs, 6, 195-211.
20. KAYE SB. (1993). P glycoprotein (P-gp) and drug resistance - time for reappraisal? (editorial). Br. J. Cancer, 67, 641-643.
21. KELLER RP, ALTERMATT HJ, NOOTER K, POSCHMANN G, LAISSUE JA, BOLLINGER P AND HIESTAND PC. (1992). SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int. J. Cancer, 50, 593-597.
22. RADEL S, BANKUSLI I, MAYHEW E AND RUSTUM YM. (1988). The effects of verapamil and a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-resistant and -sensitive leukemia in vitro and in vivo. Cancer Chemother. Pharmacol., 21, 25-30.
23. RADERER M AND SCHEITHAUER W. (1993). Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer, 72, 3553-3563.
24. RODENBURG CJ, NOOTER K, HERWEIJER H, SEYNAEVE C, OOSTEROM R, STOTER G AND VERWEIJ J. (1991). Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann. Oncol., 2, 305-306.
25. SIKIC BI. (1993). Modulation of multidrug resistance: at the threshold (editorial; comment). J. Clin. Oncol., 11, 1629-1635.
26. THIEBAUT F, TSURUO T, HAMADA H, GOTTESMAN MM, PASTAN I AND WILLINGHAM MC. (1987). Cellular localization of the multdrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. U.S.A., 84, 7735-7738.
27. TSURUO T AND TOMIDA A. (1995). Multidrug resistance. Anticancer Drugs, 6, 213-218.
28. TWENTYMAN PR AND BLEEHEN NM. (1991). Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A. Eur. J. Cancer, 27, 1639-1642.